The Experts below are selected from a list of 14904 Experts worldwide ranked by ideXlab platform

Massimo Cristofanilli - One of the best experts on this subject based on the ideXlab platform.

  • international consensus on the clinical management of Inflammatory Breast Cancer from the morgan welch Inflammatory Breast Cancer research program 10th anniversary conference
    Journal of Cancer, 2018
    Co-Authors: Naoto T. Ueno, Massimo Cristofanilli, Huong T Lepetross, Jose Rodrigo Espinosa Fernandez, Beth Overmoyer, Daniel Rea, Fedor Berdichevski, Mohamad Elshinawi, Jennifer R Bellon, Anthony Lucci
    Abstract:

    National and international experts in Inflammatory Breast Cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center in Houston Texas. A consensus on the clinical management of patients with IBC was discussed, summarized, and subsequently reviewed. All participants at the conference (patients, advocates, researchers, trainees, and clinicians) were queried using the MDRing electronic survey on key management issues. A summary of the expert consensus and participant voting is presented. Bilateral Breast and nodal evaluation, Breast magnetic resonance imaging, positron emission tomography/computed tomography, and medical photographs were endorsed as optimal. Neoadjuvant systemic therapy, modified radical mastectomy and level I and II ipsilateral axillary node dissection, post-mastectomy radiotherapy, adjuvant targeted therapy and hormonal therapy as indicated, and delayed reconstruction were agreed-upon fundamental premises of standard non-protocol-based treatment for IBC. Consideration for local-regional therapy in de novo stage IV IBC was endorsed to provide local control whenever feasible. Variation across centers and special circumstances were discussed.

  • The Third International Inflammatory Breast Cancer Conference
    Breast Cancer Research, 2013
    Co-Authors: Kenneth L. Van Golen, Massimo Cristofanilli
    Abstract:

    Inflammatory Breast Cancer (IBC) is the most aggressive and deadly form of Breast Cancer. Disease-specific research and conferences have been organized since 2008 with the intent to bring together experts in various disciplines. This report focus on the Third International IBC Conference held in Philadelphia on December 2012.

  • A global approach to Inflammatory Breast Cancer.
    Future Oncology, 2011
    Co-Authors: Fredika M. Robertson, Massimo Cristofanilli
    Abstract:

    Inflammatory Breast Cancer (IBC) is the most aggressive and deadly form of Breast Cancer. In spite of the comprehensive multidisciplinary approach to the management of this disease, the prognosis remains dismal. Moreover, there have been no major advancements in understanding the etiology and biology of IBC and no significant improvements in the diagnosis of the disease. The International Inflammatory Breast Cancer Conference was established in 2008 with the intention of creating a forum for the discussion, collaboration and development of proposals and working hypotheses. Furthermore, the conference represented an opportunity to raise awareness regarding IBC. The second international conference reported on several new exciting projects based on work from investigators and research teams devoted to making a difference in the fight against this disease.

  • Inflammatory Breast Cancer: what progress have we made?
    Oncology (Williston Park N.Y.), 2011
    Co-Authors: Shaheenah Dawood, Massimo Cristofanilli
    Abstract:

    Over the past decade, Inflammatory Breast Cancer (IBC), a rare and aggressive subtype of locally advanced Breast Cancer (LABC), has received much attention at the level of public awareness as well as at the level of research.

  • Inflammatory Breast Cancer
    Journal of the National Comprehensive Cancer Network, 2011
    Co-Authors: Holly Dushkin, Massimo Cristofanilli
    Abstract:

    Inflammatory Breast Cancer (IBC) is the most aggressive form of primary Breast Cancer, with the optimal treatment methods remaining a challenge, primarily due to the early onset of metastasis and rapid tumor progression. In the United States, the incidence is low, reported as 1–6 % of all Breast Cancers. Data from the Surveillance, Epidemiology, and End Results Program (SEER) revealed that IBC incidence rates between 1988–1990 and 1997–1999 increased from 2 to 2.5 (per 100,000 women-years) (p < 0.001), whereas those with locally advanced Breast Cancer (LABC) declined (2.5–2.0; p = 0.0025). Improvement in systemic treatment and locoregional managements with surgery and radiation are a crucial part of the curative treatment program of IBC, and several studies have shown the improvement in locoregional control and overall survival when patients are treated with chemotherapy. However, despite the use of multidisciplinary treatment for the IBC, the 5-year survival remains at approximately 30–40 %, with no significant change in the overall prognosis over the past 30 years.

Gabriel N. Hortobagyi - One of the best experts on this subject based on the ideXlab platform.

  • Inflammatory Breast Cancer pet ct mri mammography and sonography findings
    Breast Cancer Research and Treatment, 2008
    Co-Authors: Wei Tse Yang, Gabriel N. Hortobagyi, Shaheenah Dawood, Homer A. Macapinlac, Selin Carkaci, Erika Resetkova, Huong T Lepetross, Ana M Gonzalezangulo, Massimo Cristofanilli
    Abstract:

    Purpose To describe the role of Positron Emission Tomography/Computed Tomography (PET/CT), Magnetic Resonance Imaging (MRI), sonography, and mammography in patients with Inflammatory Breast Cancer (IBC).

  • Inflammatory Breast Cancer: PET/CT, MRI, mammography, and sonography findings
    Breast Cancer Research and Treatment, 2007
    Co-Authors: Wei Tse Yang, Gabriel N. Hortobagyi, Shaheenah Dawood, Huong T. Le-petross, Homer A. Macapinlac, Selin Carkaci, Ana M. Gonzalez-angulo, Erika Resetkova, Massimo Cristofanilli
    Abstract:

    Purpose To describe the role of Positron Emission Tomography/Computed Tomography (PET/CT), Magnetic Resonance Imaging (MRI), sonography, and mammography in patients with Inflammatory Breast Cancer (IBC).

  • Inflammatory Breast Cancer: Clinical progress and the main problems that must be addressed
    Breast Cancer Research, 2003
    Co-Authors: Sharon H Giordano, Gabriel N. Hortobagyi
    Abstract:

    Inflammatory Breast Cancer is a rare but highly aggressive form of locally advanced Breast Cancer. Historically, this disease was uniformly fatal; however, with the advent of induction chemotherapy and carefully coordinated multimodality treatment, the prognosis of these patients has improved. This article reviews the clinical characteristics of Inflammatory Breast Cancer and the recent advances in therapy.

  • Inflammatory Breast Cancer: a review.
    Journal of Clinical Oncology, 1992
    Co-Authors: Ishmael Jaiyesimi, Aman U. Buzdar, Gabriel N. Hortobagyi
    Abstract:

    PURPOSEThe natural history of Inflammatory Breast Cancer and the recent advances in its management were reviewed.DESIGNThe English medical literature from 1924 to 1990 was reviewed using the Cancerline and Medline retrieval systems, and through a manual review of bibliographies of identified articles.RESULTSThe majority of patients with Inflammatory Breast Cancer treated only with local therapies died 18 to 24 months after diagnosis. A combined modality approach with chemotherapy, surgery, and radiation therapy has improved disease-free and overall survival rates for Inflammatory Breast Cancer. Approximately 35% to 55% of patients treated with combined modality regimens remain disease-free and alive at 5 years.CONCLUSIONInduction combination chemotherapy administered with radiation therapy, mastectomy, both, or with additional chemotherapy favorably alters the natural history of Inflammatory Breast Cancer. New drug combinations and high-dose chemotherapy with autologous bone marrow support are being evalu...

Wendy A. Woodward - One of the best experts on this subject based on the ideXlab platform.

  • Immune and molecular determinants of response to neoadjuvant chemotherapy in Inflammatory Breast Cancer.
    Journal of Clinical Oncology, 2017
    Co-Authors: Sangeetha M. Reddy, Savitri Krishnamurthy, Wendy A. Woodward, James M. Reuben, Naoto T. Ueno, Jennifer A. Wargo, Alexandre Reuben, Michael T. Tetzlaff, Jason Roszik, Elizabeth A. Mittendorf
    Abstract:

    11501Background: Inflammatory Breast Cancer (IBC) is the most aggressive form of primary Breast Cancer and has poor responses to standard of care neoadjuvant chemotherapy (NAC). Given there is a li...

  • Inflammatory Breast Cancer a proposed conceptual shift in the uicc ajcc tnm staging system
    Lancet Oncology, 2017
    Co-Authors: Bora Lim, Wendy A. Woodward, Anthony Lucci, James M. Reuben, Tamer M. Fouad, Michael C. Stauder, Sarah M. Desnyder, Angelica Gutierrez M Barrera, Banu Arun
    Abstract:

    Summary In the absence of histological criteria that distinguish between Inflammatory and non-Inflammatory Breast Cancer, diagnosis of Inflammatory Breast Cancer relies entirely on the existence of clinical criteria as outlined by the TNM classification. This classification restricts patients presenting with clinical criteria characteristic of Inflammatory Breast Cancer to subcategory T4d, which immediately relegates all patients with non-metastatic Inflammatory Breast Cancer to stage 3, regardless of tumour size or nodal spread. Patients who present with metastatic disease are consigned to stage 4, and the TNM classification does not distinguish patients on the basis of the presence of Inflammatory criteria. Evidence by our group and others suggests that patients with Inflammatory Breast Cancer have significantly reduced overall survival among those who present with distant metastasis at diagnosis (stage 4). In light of these results, this Personal View addresses whether the current TNM staging classification accurately represents a distinction between patients with Inflammatory and those with non-Inflammatory Breast Cancer.

  • Identification of frequent somatic mutations in Inflammatory Breast Cancer
    Breast Cancer Research and Treatment, 2017
    Co-Authors: Naoko Matsuda, Bora Lim, Ying Wang, Savitri Krishnamurthy, Wendy A. Woodward, Ricardo H. Alvarez, Anthony Lucci, Vicente Valero, James M. Reuben, Funda Meric-bernstam
    Abstract:

    Purpose Inflammatory Breast Cancer is an aggressive form of Breast Cancer that shows distinct clinical features from non-Inflammatory Breast Cancer. Genomic understanding of Inflammatory Breast Cancer will shed light on biological targets for this disease. Our objective was to identify targeted hotspot mutations using multiplex genome sequencing in Inflammatory Breast Cancer and compare the findings with those for patients with non-Inflammatory Breast Cancer to further recognize novel targets.

  • Inflammatory Breast Cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system
    The Lancet Oncology, 2017
    Co-Authors: Tamer M. Fouad, Bora Lim, Wendy A. Woodward, Anthony Lucci, James M. Reuben, Angelica M. Gutierrez Barrera, Michael C. Stauder, Sarah M. Desnyder, Banu Arun, Babiera Gildy
    Abstract:

    Summary In the absence of histological criteria that distinguish between Inflammatory and non-Inflammatory Breast Cancer, diagnosis of Inflammatory Breast Cancer relies entirely on the existence of clinical criteria as outlined by the TNM classification. This classification restricts patients presenting with clinical criteria characteristic of Inflammatory Breast Cancer to subcategory T4d, which immediately relegates all patients with non-metastatic Inflammatory Breast Cancer to stage 3, regardless of tumour size or nodal spread. Patients who present with metastatic disease are consigned to stage 4, and the TNM classification does not distinguish patients on the basis of the presence of Inflammatory criteria. Evidence by our group and others suggests that patients with Inflammatory Breast Cancer have significantly reduced overall survival among those who present with distant metastasis at diagnosis (stage 4). In light of these results, this Personal View addresses whether the current TNM staging classification accurately represents a distinction between patients with Inflammatory and those with non-Inflammatory Breast Cancer.

  • Inflammatory Breast Cancer: unique biological and therapeutic considerations.
    The Lancet Oncology, 2015
    Co-Authors: Wendy A. Woodward
    Abstract:

    Summary Through the concerted efforts of many patients, health-care providers, legislators, and other supporters, the past decade has seen the development of the first clinics dedicated to the care of patients with Inflammatory Breast Cancer in the USA and other countries. Together with social networking, advocacy, and education, a few specialised centres have had substantial increases in patient numbers (in some cases ten times higher), which has further expanded the community of science and advocacy and increased the understanding of the disease process. Although Inflammatory Breast Cancer is considered rare, constituting only 2–4% of Breast Cancer cases, poor prognosis means that patients with the disease account for roughly 10% of Breast Cancer mortality annually in the USA. I propose that the unique presentation of Inflammatory Breast Cancer might require specific, identifiable changes in the Breast parenchyma that occur before the tumour-initiating event. This would make the Breast tissue itself a tumour-promoting medium that should be treated as a component of the pathology in multidisciplinary treatment and should be further studied for complementary targets to inhibit the pathobiology that is specific to Inflammatory Breast Cancer.

Wei Tse Yang - One of the best experts on this subject based on the ideXlab platform.

Shaheenah Dawood - One of the best experts on this subject based on the ideXlab platform.

  • Inflammatory Breast Cancer: what progress have we made?
    Oncology (Williston Park N.Y.), 2011
    Co-Authors: Shaheenah Dawood, Massimo Cristofanilli
    Abstract:

    Over the past decade, Inflammatory Breast Cancer (IBC), a rare and aggressive subtype of locally advanced Breast Cancer (LABC), has received much attention at the level of public awareness as well as at the level of research.

  • Biology and management of Inflammatory Breast Cancer
    Expert Review of Anticancer Therapy, 2010
    Co-Authors: Shaheenah Dawood
    Abstract:

    Inflammatory Breast Cancer is an aggressive subtype of a locally advanced Breast Cancer that is thought to account for approximately 1–5% of all newly diagnosed Breast Cancers diagnosed in the USA. Historically, IBC was considered to be a uniformly fatal disease with less than 5% of patients surviving past 5 years. With the advent of a multidisciplinary approach to management, survival outcomes have improved with 5-year survival rates of over 40% being reported. Research efforts are now focused on trying to better understand the epidemiological and molecular characteristics of this disease to further improve survival. Two genes, Rhoc GTPase and WISP3, have been identified that have been found to be concordantly altered in the majority of Inflammatory Breast Cancer tumors and may serve as potential targets for future therapeutic agents. The purpose of this review is to summarize the latest epidemiological and molecular characteristics of IBC, describe the difficulties encountered in trying to clinically di...

  • Inflammatory Breast Cancer pet ct mri mammography and sonography findings
    Breast Cancer Research and Treatment, 2008
    Co-Authors: Wei Tse Yang, Gabriel N. Hortobagyi, Shaheenah Dawood, Homer A. Macapinlac, Selin Carkaci, Erika Resetkova, Huong T Lepetross, Ana M Gonzalezangulo, Massimo Cristofanilli
    Abstract:

    Purpose To describe the role of Positron Emission Tomography/Computed Tomography (PET/CT), Magnetic Resonance Imaging (MRI), sonography, and mammography in patients with Inflammatory Breast Cancer (IBC).

  • The medical treatment of Inflammatory Breast Cancer.
    Seminars in Oncology, 2008
    Co-Authors: Shaheenah Dawood, Naoto T. Ueno, Massimo Cristofanilli
    Abstract:

    The multidisciplinary management of Inflammatory Breast Cancer (IBC) includes neoadjuvant systemic chemotherapy, surgery, radiotherapy, and, in hormone receptor-positive disease, hormonal therapy. The use of induction chemotherapy with anthracyclines and taxanes somewhat improved the prognosis and local control of patients with IBC compared to local modalities alone. Improved understanding of the biological features of the disease has allowed for the development of targeted therapies (eg, trastuzumab and lapatinib) that are changing the outcome of this aggressive disease.

  • Inflammatory Breast Cancer: PET/CT, MRI, mammography, and sonography findings
    Breast Cancer Research and Treatment, 2007
    Co-Authors: Wei Tse Yang, Gabriel N. Hortobagyi, Shaheenah Dawood, Huong T. Le-petross, Homer A. Macapinlac, Selin Carkaci, Ana M. Gonzalez-angulo, Erika Resetkova, Massimo Cristofanilli
    Abstract:

    Purpose To describe the role of Positron Emission Tomography/Computed Tomography (PET/CT), Magnetic Resonance Imaging (MRI), sonography, and mammography in patients with Inflammatory Breast Cancer (IBC).